【#茅台原董事长张德芹新任职#】12月5日，贵州省工商联工作人员向红星资本局确认，贵州茅台原董 事长张德芹已赴贵州省工商业联合会上任，分管党组工作。10月25日上午，茅台集团宣布，张德芹不再 担任茅台集团董事长职务，另作他任。2024年4月，张德芹接任丁雄军，成为茅台集团董事长及上市公 司贵州茅台董事长，在任时间一年半。（红星新闻） ...

（企业公告） 截止到2025年11月底，塔斯汀在营门店数11124家。2025年1-11月闭店数为67家，迁址店数为238家。该第三方数据监 测平台在发布数据前，从未与品牌进行任何沟通和核实。 12月5日，塔斯汀发布声明。表示近期媒体涉及品牌加盟数据的相关报道中，引用了"极海品牌监测"关于塔斯汀的开闭 店数据,该数据严重失实。 对"极海品牌监测"及其他第三方平台发布失实数据的行为，塔斯汀保留追究法律责任的权利。 ...

Core Viewpoint - The company has decided to delay the global offering and listing of its H-shares due to market conditions, with a commitment to timely information disclosure regarding future developments [1] Group 1: Financial Performance and Collaborations - The significant increase in net profit for 2024 is primarily attributed to a major licensing collaboration with BMS, raising concerns about the sustainability of long-term profitability due to potential "one-time revenue" perceptions [1] - The company has received an upfront payment of $800 million from BMS, which is non-refundable and non-offsettable, with actual amounts subject to bank fees [1] - The company is eligible for additional payments of up to $250 million for recent or contingent milestones, and up to $7.1 billion for achieving specific development, registration, and sales milestones [1] Group 2: Clinical Development Pipeline - The company has successfully developed three core clinical assets in Phase III (iza-bren, T-Bren, and SI-B001) and 14 early-stage core clinical assets, including 8 ADC drugs and 4 GNC drugs [2] - Over 90 clinical trials are being conducted globally, with more than 80 trials in China and 10 in the United States [2] Group 3: Specific Drug Developments - Iza-bren is a first-in-class dual-target ADC that has initiated over 40 clinical trials for more than 10 types of tumors, with significant trials ongoing in both the U.S. and China [3] - T-Bren is an innovative ADC targeting HER2, currently undergoing 14 clinical trials, including 5 Phase III trials, demonstrating significant anti-tumor efficacy [4]

Core Viewpoint - The company, Pang Donglai, has announced a long-term recruitment initiative aimed at attracting top talent from various professional fields globally [1] Group 1: Recruitment Announcement - The recruitment initiative is titled "Top Talent Fast Track in Professional Fields" and aims to attract talent with a global perspective and cross-cultural collaboration skills [1] - Candidates are expected to possess industry expertise at an international forefront level and the ability to create innovative value and professional standards within teams [1] - The company emphasizes the need for candidates to have systematic and forward-thinking strategic capabilities, as well as high-quality decision-making skills [1] Group 2: Candidate Requirements - The desired professional fields for applicants include cultural studies, human resources, product development, quality management, safety management, information technology, financial management, engineering project management, brand art design, and corporate legal affairs [1] - There are no restrictions on gender or nationality for applicants, but candidates must be 50 years old or younger [1] Group 3: Compensation and Benefits - Pang Donglai offers a minimum of 60 days of paid leave and an annual salary of no less than 1 million yuan, with senior talent compensation to be discussed during interviews [1]

其出让模式能够优化土地资源配置，避免闲置浪费，契合集约用地导向。 广州将迎来土拍密集出让期。 中指研究院广州分院研究主管陈雪强表示，该地块区位优势明显，位处成熟的海珠西板块，因此竞拍前 就吸引了中海、保利、越秀、华润、绿城等多家房企关注。 从周边竞品看，板块内新房多以"蚊型盘""超高层" 为主，在售主力楼盘如保利燕语堂悦、绿城馥香园 等规模不超过5-8栋楼。还有如中建天珏、越秀桂悦东晓、中旅天宸府府等项目大多在2-4栋楼。且周边 手房多以20年左右楼龄的小区为主，密度高、户型老，有较强烈的改善需求。 业内人士表示，此次所拍地块是海珠西较为罕见的低密大盘，这种供需错配的背景下，也正是南泰路地 块吸引房企争抢的核心原因。 据不完全统计，截至目前，今年广州已经出让51宗宅地，共揽金约358亿元，不到去年772亿元的一半。 因此，接下来，广州将上架20宗宅地，总价超254亿元。综合来看，这些地块既有主城区核心板块优质 宅地，也有郊区醇熟宅地。其中南沙区有5宗宅地，数量最多，均有此前"商改住"调规而来。20宗宅地 有12宗占地不足5万平， 白云、天河、荔湾、海珠等市中心核心地块体量均较小。 业内分析认为，在当前市场格局 ...

Core Insights - L'Oréal's China R&D and Innovation Center is driving global beauty giant's performance through localized product innovations tailored for Chinese consumers [1][2] - The center has evolved into a key pillar in L'Oréal's global R&D landscape, emphasizing collaboration with local scientific institutions and startups to enhance innovation capabilities [4][5] Group 1: Product Innovations - Customized products such as a jasmine-scented cream and a lip gloss inspired by local culinary flavors are examples of L'Oréal's localized approach [1] - The "P-TIOX" peptide serum, developed by the Chinese R&D team, has been highlighted as a major contributor to sustained double-digit growth for the brand [2] Group 2: R&D Achievements - Over the past 20 years, L'Oréal's China R&D has conducted approximately 35 large-scale foundational research projects, involving over 100,000 Chinese consumers annually [7] - In 2024, the center is set to publicly file 372 patents, with 81 of those being inventions from the Chinese R&D team [7] Group 3: Collaborations and Investments - L'Oréal has engaged in strategic investments in local biotech firms, such as "Unnamed Light," to co-develop innovative bioactive ingredients and promote sustainable production methods [10][11] - The establishment of the "Academician Workstation" in collaboration with Shanghai Jiao Tong University marks a significant milestone in L'Oréal's commitment to local scientific advancement [9] Group 4: Market Strategy - L'Oréal's investment strategy includes backing emerging local brands like LANlan, which aligns with the company's long-term vision of investing in the future of the Chinese market [15][16] - The company aims to leverage its R&D capabilities to support the commercialization of innovative products and enhance the overall beauty ecosystem in China [12][16]

近日，第111届北美放射学会年会（RSNA 2025）在美国芝加哥举办。在这场全球医学影像盛会上，国产医疗器械龙头 迈瑞医疗携超高端全身应用超声Resona A20等超声创新产品及解决方案重磅亮相，向世界展示了中国医疗器械企业在 超高端影像领域的的创新实力。 值得注意的是，这是迈瑞医疗的超高端超声产品首次在北美地区亮相。依托自主研发的核心技术与全球化的市场布 局，迈瑞医疗的此次亮相不仅彰显了中国医疗科技的硬核实力，还标志着其超声业务在北美市场进入新阶段，为后续 的海外市场发展带来更多可能。 超高端产品跻身全球技术第一梯队 资料显示，迈瑞医疗的超高端全身应用超声Resona A20是业内首款在临床环境下实现超分辨率血流成像的超声设备。 凭借完全自主研发的探头与创新技术，Resona A20将传统超声的毫米级成像能力提升至微米级。而这一技术突破可帮 助医生发现直径小于5毫米的肝脏肿瘤，对肿瘤早期诊断及良恶性鉴别具有重大临床价值。 自2023年国内上市后，Resona A20已陆续获得欧盟CE、美国FDA等认证，其搭载的核心创新技术与突破性性能也获得 全球核心市场的认可，产品在欧洲、中东的高端客户群体中均迅速实现突 ...

（东方财富网） (编辑：王璨 林辰) 12月5日，遇见小面于港交所主板上市。该日，遇见小面开盘报5.00港元/股，收盘报5.08港元/股，跌幅 27.84%，公司总市值为36.1亿港元。 ...

此外，针对前三季度加盟店占比变化，元祖股份还称，公司前三季度加盟店占比21%，较去年微增。 （企业公告） 12月5日，元祖股份发布投资者关系活动记录表。当中披露，关于前三季度公司业绩变动的核心因素， 元祖股份指出，今年中秋较去年同期延后，部分营收体现在10月份。另外，公司下半年积极拓展市场， 于上海虹桥机场、深圳、泉州等地开设了首批门店。未来将继续推进"有节、有礼、有元祖"的产品理 念，以更丰富的产品满足市场需求。 (编辑：王璨 林辰)关键字： 食品 元祖股份 ...

【#年内上市新股打新盈利均值1.91万元#】#摩尔线程年内打新盈利最高股票#证券时报·数据宝统计，截 至12月5日收盘，2025年上市新股共101只。按照上交所、深交所中签500股，北交所中1签100股计算， 若以上市首日开盘价卖出，2025年上市新股中，投资者中1签的打新盈利均值达到1.91万元。打新盈利 最高的股票是摩尔线程，该股上市首日开盘价为650元/股，打新盈利达到26.79万元，且远远超过第二 名的水平。（证券时报） ...